Ribociclib plus standard-of-care endocrine therapy significantly improved overall survival for younger women with advanced hormone receptor-positive breast cancer vs endocrine therapy alone.
Medscape Medical News …read more
Ribociclib plus standard-of-care endocrine therapy significantly improved overall survival for younger women with advanced hormone receptor-positive breast cancer vs endocrine therapy alone.
Medscape Medical News …read more